Key result
DCB shows no benefit over DES for major cardiovascular events in CKD patients undergoing PCI.
Why the study?
Patients with CKD undergoing PCI face high ischemic and bleeding risks, and drug-coated balloons avoid a permanent implant and permit shorter dual antiplatelet therapy, motivating a synthesis of outcomes compared with drug-eluting stents.
Does treatment with drug-coated balloons reduce the composite of major adverse cardiovascular or device-oriented events compared to drug-eluting stents in adults with chronic kidney disease undergoing percutaneous coronary intervention?
Meta-Analysis (n=2,527)
Does treatment with drug-coated balloons reduce the composite of major adverse cardiovascular or device-oriented events compared to drug-eluting stents in adults with chronic kidney disease undergoing percutaneous coronary intervention?
In patients with chronic kidney disease undergoing percutaneous coronary intervention, drug-coated balloons demonstrated comparable efficacy to drug-eluting stents for major adverse cardiovascular or device-oriented events, with zero events of lesion thrombosis in the DCB group.
Answers are grounded in this paper and cite their sources.
Supports DCB as a stent-free alternative to DES in CKD-PCI; extends options for minimizing implant-related risks in high-bleeding-risk patients.
Patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) face high ischemic and bleeding risks. Drug-coated balloons (DCB) avoid a permanent implant and permit shorter dual antiplatelet therapy. We searched PubMed, Embase, Scopus, and Web of Science through May 2026 for studies comparing DCB with drug-eluting stents (DES) in adults with CKD undergoing PCI. Study-level hazard ratios (HRs) were pooled with random-effects inverse-variance models; individual patient data (IPD) were reconstructed from published Kaplan-Meier curves, and certainty was rated with Grading of Recommendations Assessment, Development and Evaluation. Five studies (two prespecified CKD analyses of randomized trials and three cohorts) comprising 2527 patients (1149 DCB and 1378 DES) were included. DCB and DES did not differ in the composite of major adverse cardiovascular or device-oriented events [HR 0.98; 95% confidence interval (CI), 0.77-1.24; IPD HR 0.96; 95% CI, 0.74-1.25], target-lesion revascularization (HR 1.02; 95% CI, 0.73-1.42), cardiac death (HR 0.94; 95% CI, 0.64-1.39), or myocardial infarction (HR 0.62; 95% CI, 0.36-1.06). Major bleeding did not differ significantly (HR 0.39; 95% CI, 0.13-1.17; IPD HR 0.51; 95% CI, 0.25-1.02). Stent or lesion thrombosis occurred only after DES (0/594 vs 12/810). Certainty was moderate for the composite endpoint and low for other outcomes.
No takes yet. Share an insight, caveat, or question.
Elbeny et al. (2026) conducted a meta-analysis in Chronic kidney disease undergoing percutaneous coronary intervention (n=2,527). Drug-coated balloons (DCB) vs. Drug-eluting stents (DES) was evaluated on Composite of major adverse cardiovascular or device-oriented events (HR 0.98, 95% CI 0.77-1.24). Drug-coated balloons did not differ from drug-eluting stents in major adverse cardiovascular or device-oriented events among CKD patients undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: